Evidence map›Paper›PMID 39602116›Full record

ArticleJAMA network open2024

Social Vulnerability, Intervention Utilization, and Outcomes in US Adults Hospitalized With Influenza.

Katherine Adams, Kimberly Yousey-Hindes, Catherine H Bozio, Seema Jain, Pam Daily Kirley, Isaac Armistead, Nisha B Alden, Kyle P Openo, Lucy S Witt, Maya L Monroe and 23 more

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Katherine AdamsInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Kimberly Yousey-HindesConnecticut Emerging Infections Program, Yale School of Public Health, New Haven.
Catherine H BozioInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Seema JainCalifornia Department of Public Health, Richmond.
Pam Daily KirleyCalifornia Emerging Infections Program, Oakland.
Isaac ArmisteadColorado Department of Public Health and Environment, Denver.
Nisha B AldenColorado Department of Public Health and Environment, Denver.
Kyle P OpenoGeorgia Emerging Infections Program, Georgia Department of Public Health, Atlanta.
Lucy S WittGeorgia Emerging Infections Program, Georgia Department of Public Health, Atlanta.
Maya L MonroeMaryland Department of Health, Baltimore.
Sue KimMichigan Department of Health and Human Services, Lansing.
Anna FalkowskiMichigan Department of Health and Human Services, Lansing.
Ruth LynfieldMinnesota Department of Health, St Paul.
Melissa McMahonMinnesota Department of Health, St Paul.
Marisa R HoffmanNew Mexico Emerging Infections Program, University of New Mexico, Albuquerque.
Yomei P ShawNew Mexico Department of Health, Santa Fe.
Nancy L SpinaNew York State Department of Health, Albany.
Adam RoweNew York State Department of Health, Albany.
Christina B FelsenUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Erin LicherdellUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Krista LungOhio Department of Health, Columbus.
Eli ShiltzOhio Department of Health, Columbus.
Ann ThomasPublic Health Division, Oregon Health Authority, Portland.
H Keipp TalbotVanderbilt University Medical Center, Nashville, Tennessee.
William SchaffnerVanderbilt University Medical Center, Nashville, Tennessee.
Melanie T CrosslandSalt Lake County Health Department, Salt Lake City, Utah.
Kristen P OlsenSalt Lake County Health Department, Salt Lake City, Utah.
Larry W ChangDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Charisse N CummingsInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Mark W TenfordeInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Shikha GargInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
James L HadlerConnecticut Emerging Infections Program, Yale School of Public Health, New Haven.
Alissa O'HalloranInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.

Funding

CDC HHS NU38OT000297Intramural CDC HHS CC999999OSTLTS CDC HHS U38 OT000143
6 · The paper itself

Abstract

Importance: Seasonal influenza is associated with substantial disease burden. The relationship between census tract-based social vulnerability and clinical outcomes among patients with influenza remains unknown. Objective: To characterize associations between social vulnerability and outcomes among patients hospitalized with influenza and to evaluate seasonal influenza vaccine and influenza antiviral utilization patterns across levels of social vulnerability. Design, Setting, and Participants: This retrospective repeated cross-sectional study was conducted among adults with laboratory-confirmed influenza-associated hospitalizations from the 2014 to 2015 through the 2018 to 2019 influenza seasons. Data were from a population-based surveillance network of counties within 13 states. Data analysis was conducted in December 2023. Exposure: Census tract-based social vulnerability. Main Outcomes and Measures: Associations between census tract-based social vulnerability and influenza outcomes (intensive care unit admission, invasive mechanical ventilation and/or extracorporeal membrane oxygenation support, and 30-day mortality) were estimated using modified Poisson regression as adjusted prevalence ratios. Seasonal influenza vaccine and influenza antiviral utilization were also characterized across levels of social vulnerability. Results: Among 57 964 sampled cases, the median (IQR) age was 71 (58-82) years; 55.5% (95% CI, 51.5%-56.0%) were female; 5.2% (5.0%-5.4%) were Asian or Pacific Islander, 18.3% (95% CI, 18.0%-18.6%) were Black or African American, and 64.6% (95% CI, 64.2%-65.0%) were White; and 6.6% (95% CI, 6.4%-68%) were Hispanic or Latino and 74.7% (95% CI, 74.3%-75.0%) were non-Hispanic or Latino. High social vulnerability was associated with higher prevalence of invasive mechanical ventilation and/or extracorporeal membrane oxygenation support (931 of 13 563 unweighted cases; adjusted prevalence ratio [aPR], 1.25 [95% CI, 1.13-1.39]), primarily due to socioeconomic status (790 of 11 255; aPR, 1.31 [95% CI, 1.17-1.47]) and household composition and disability (773 of 11 256; aPR, 1.20 [95% CI, 1.09-1.32]). Vaccination status, presence of underlying medical conditions, and respiratory symptoms partially mediated all significant associations. As social vulnerability increased, the proportion of patients receiving seasonal influenza vaccination declined (-19.4% relative change across quartiles; P < .001) as did the proportion vaccinated by October 31 (-6.8%; P < .001). No differences based on social vulnerability were found in in-hospital antiviral receipt, but early in-hospital antiviral initiation (-1.0%; P = .01) and prehospital antiviral receipt (-17.3%; P < .001) declined as social vulnerability increased. Conclusions and Relevance: In this cross-sectional study, social vulnerability was associated with a modestly increased prevalence of invasive mechanical ventilation and/or extracorporeal membrane oxygenation support among patients hospitalized with influenza. Contributing factors may have included worsened baseline respiratory health and reduced receipt of influenza prevention and prehospital or early in-hospital treatment interventions among persons residing in low socioeconomic areas.

Indexed as

Antiviral AgentsHospitalizationInfluenza, HumanInfluenza VaccinesSocial VulnerabilityAdultAgedAged, 80 and overCross-Sectional StudiesExtracorporeal Membrane OxygenationFemaleHumansMaleMiddle AgedRetrospective StudiesUnited StatesAntiviral AgentsInfluenza Vaccines

Identifiers

PMID39602116
PMCPMC11702903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.